OrthoPediatrics Corp. Files 8-K on Financials
Ticker: KIDS · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1425450
| Field | Detail |
|---|---|
| Company | Orthopediatrics Corp (KIDS) |
| Form Type | 8-K |
| Filed Date | Oct 9, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00025 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: KIDS
TL;DR
OrthoPediatrics (KIDS) dropped an 8-K with financial updates. Check it out.
AI Summary
OrthoPediatrics Corp. filed an 8-K on October 9, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance. OrthoPediatrics Corp. is incorporated in Delaware and its common stock trades on the Nasdaq under the ticker symbol KIDS.
Why It Matters
This filing provides investors with updated financial information and operational results for OrthoPediatrics Corp., crucial for assessing the company's current performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) that does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- OrthoPediatrics Corp. (company) — Registrant
- KIDS (company) — Trading Symbol
- Nasdaq (company) — Exchange
- October 9, 2025 (date) — Report Date
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of the financial results are not provided in this summary.
When was this 8-K filed?
This 8-K was filed on October 9, 2025.
What is the principal business address of OrthoPediatrics Corp.?
The principal executive offices are located at 2850 Frontier Drive, Warsaw, Indiana 46582.
What is the trading symbol for OrthoPediatrics Corp. common stock?
The trading symbol is KIDS.
On which exchange is OrthoPediatrics Corp. common stock traded?
The common stock is traded on the Nasdaq.
Filing Stats: 747 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2025-10-09 16:06:28
Key Financial Figures
- $0.00025 — ange on which registered Common Stock, $0.00025 par value per share KIDS Nasdaq Global
Filing Documents
- kids-20251009.htm (8-K) — 28KB
- kidsprelim3q25v4-finalsa.htm (EX-99.1) — 11KB
- kidsprelim3q25v4-finalsa001.jpg (GRAPHIC) — 244KB
- kidsprelim3q25v4-finalsa002.jpg (GRAPHIC) — 282KB
- kidsprelim3q25v4-finalsa003.jpg (GRAPHIC) — 187KB
- 0001425450-25-000108.txt ( ) — 1155KB
- kids-20251009.xsd (EX-101.SCH) — 2KB
- kids-20251009_def.xml (EX-101.DEF) — 3KB
- kids-20251009_lab.xml (EX-101.LAB) — 24KB
- kids-20251009_pre.xml (EX-101.PRE) — 15KB
- kids-20251009_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 9, 2025, OrthoPediatrics Corp. (the "Company") issued a press release announcing its preliminary unaudited net revenue for the third quarter ended September 30, 2025, revised financial guidance for the year ending December 31, 2025, and provided business updates. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The financial information set forth in this Form 8-K reflects the Company's current preliminary net revenue estimates, is subject to the completion of its audit process, and is subject to change. The Company's results for the third quarter ended September 30, 2025 could differ materially from the preliminary estimates provided in this form 8-K. The Company's net revenue for the full year ending December 31, 2025 could also differ materially from the forecasted amounts. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form 8-K. You should refer to the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 5, 2025, as updated and supplemented by our other SEC reports filed from time to time, for a discussion of important factors that may cause our actual results and net revenue to differ materially from those expressed or implied by these forward-looking statements. Given these risks, uncert
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Orthopediatrics Corp. Revenue and Revised 2025 Guidance dated October 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * * * * * * SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OrthoPediatrics Corp. Date: October 9, 2025 By: /s/ Daniel J. Gerritzen Daniel J. Gerritzen, General Counsel and Secretary - 2 -